World Orphan Drug Congress USA focusses on the most pressing challenges and opportunities to bring rare disease therapies to patients faster.
Walter Colasante, Vice President in the Life Sciences Practice, will be speaking on “Value assessment is different for Rare Diseases, requiring new thinking to build consensus around access decisions” and Charles River Associates is a silver sponsor at this year’s conference.
For more information on this event, click here.
Part 4: Inflation Reduction Act: The indirect effects and implications of IRA price negotiations
Since passage of the Inflation Reduction Act (IRA) in August 2022, the focus of many industry analysts and pharmaceutical companies has been on two important...